grapesharvester schreef op 20 januari 2016 22:55:
[...]
There are more people that do not see a clear picture as yet (IMHO):
Vertex listed by Credit Suisse as one of the 6 top biotechs:
The Credit Suisse price objective for Vertex is $151. The company has no real competition in sight, and Credit Suisse thinks its advantage is sustainable due to innovation. The firm also sees upside with the HetMin opportunity. Vertex shares were trading down 3.1% at $92.01, with a consensus analyst target of $146.50 and a 52-week range of $91.92 to $143.45.
--------------------------
Vertex has no competition in sight for CF???